Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.17 (
MMP-3
)
3,419
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
One of the primary antioxidant enzymes,
manganese-containing superoxide dismutase
(
MnSOD
), has shown the ability to reverse malignant phenotypes in a variety of human tumor cells that are low or absent in
MnSOD
expression. We have observed that overexpression of human
MnSOD
in human breast cancer MCF-7 cells inhibits tumor growth both in vitro and in vivo. The signaling pathway underlying the
MnSOD
induced tumor suppression is unknown. We demonstrate here that transcriptional and DNA binding ability of AP-1 and NF-kappaB, but not SP-1, were inhibited (by 50%) in the MCF-7 cell line overexpressing
MnSOD
. When transiently expressing,
MnSOD
inhibited AP-1 but increased NF-kappaB transactivation, which can be abolished by sodium pyruvate, a hydrogen peroxide scavenger. To analyze the target genes responsible for
MnSOD
-induced tumor suppression, genes related to tumor growth and responsive to AP-1 or NF-kappaB were analyzed. AP-1 responsive collagenase I,
stromelysin
I, and NF-kappaB responsive IL-1 and IL-6 were down-regulated in the
MnSOD
stable transfectants compared to the control cell lines. Since TPA induces differentiation in human breast cancer cells and up-regulates
MnSOD
gene in HeLa cells,
MnSOD
expression and AP-1 and NF-kappaB activity were measured under TPA treatment. The results showed that TPA induced endogenous
MnSOD
expression and inhibited both AP-1 and NF-kappaB. Together, these results suggest that tumor suppression by overexpressing
MnSOD
is related to a modulation of AP-1 and NF-kappaB, which causes a down-regulation of genes responsible for tumor malignant phenotype.
...
PMID:Inhibition of AP-1 and NF-kappaB by manganese-containing superoxide dismutase in human breast cancer cells. 983 61